News
Updates: Lilly's Global COVID-19 Response
View Story
Naming a New Drug During a Pandemic
View Story
Time to Tear Down the Rebate Wall
View Story
Lilly's COVID-19 Science Leads to a Second FDA Emergency Use Authorization
View Story
When the World Called for Help with COVID-19, We Were Ready
View Story
Dave Ricks Shares About Lilly's FDA Emergency Use Authorization for a Neutralizing Antibody
View Story
December 5, 2020
Tags | Product
52% overall response rate in mantle cell lymphoma patients previously treated with a covalent BTK inhibitor 83% of responding mantle cell lymphoma patients remain in response and on therapy 68% overall response rate in patients with Waldenström's macroglobulinemia, 69% of whom were previously
December 4, 2020
Tags | Product
The study brings together symptom tracking, in-home testing and in-home infusions to detect, intercept and treat COVID-19 early INDIANAPOLIS and MINNETONKA, Minn. , Dec. 4, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and UnitedHealth Group (NYSE: UNH) today announced a partnership to
December 2, 2020
Tags | Product
INDIANAPOLIS , Dec. 2, 2020 /PRNewswire/ -- The U.S. government has purchased 650,000 additional doses of Eli Lilly and Company's (NYSE: LLY) neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. The purchase agreement is for $812.5 million and the doses will be delivered through January 31, 2021
November 24, 2020
Tags | Financial
INDIANAPOLIS , Nov. 24, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Evercore ISI 3 rd Annual HealthCONx Conference on Tuesday, December 1, 2020 . Michael Mason , Lilly senior vice president and president of Lilly Diabetes and Connected Care, will participate in a